Company
Headquarters: Malvern, PA, United States
Employees: 108
CEO: Mr. Antony Koblish
$80.7 Million
USD as of July 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $58.5 M |
| EBITDA | $-43,267,000 |
| Gross Profit TTM | $40.1 M |
| Profit Margin | -79.83% |
| Operating Margin | -72.23% |
| Quarterly Revenue Growth | 46.30% |
TELA Bio, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TELA